We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Donor-Linked Biomarker Predicts Likelihood of Liver Transplant Success

By LabMedica International staff writers
Posted on 31 Aug 2021
Print article
Image: A healthy human liver. A biomarker linked to the organ donor predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ (Photo courtesy of  Wikimedia Commons)
Image: A healthy human liver. A biomarker linked to the organ donor predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ (Photo courtesy of Wikimedia Commons)
A recent paper identified a biomarker linked to the organ donor that predicts the likelihood that a transplanted liver will be accepted or rejected by the recipient of the organ.

Compatibility between donor and recipient depends on the similarity of the HLA (human leukocyte antigen) proteins expressed by both. A measure of this similarity is the HLA evolutionary divergence (HED), a continuous metric that quantifies the peptidic differences between two homologous HLA alleles, reflecting the size of the immunopeptide region resented to T-lymphocytes.

In this recent paper, investigators at Assistance Publique, Hôpitaux de Paris, (France) sought to assess the potential effect of donor or recipient HED on liver transplant rejection.

For this study, they accessed the medical records of 1154 adults and 113 children who had a liver transplant between 2004 and 2018. Liver biopsies were done one, two, five, and 10 years after the transplant and in case of liver dysfunction. Donor-specific anti-HLA antibodies (DSAs) were measured in children at the time of biopsy. The HED was calculated using the physicochemical Grantham distance for class I (HLA-A or HLA-B) and class II (HLA-DRB1 or HLA-DQB1) alleles. Grantham's distance depends on three properties: composition, polarity and molecular volume. According to Grantham's distance, the most similar amino acids are leucine and isoleucine and the most distant are cysteine and tryptophan.

The influence of HED on the incidence of liver lesions was analyzed through the inverse probability weighting approach based on covariate balancing, generalized propensity scores.

Data obtained during the study showed that in adults, class I HED of the donor was associated with acute rejection, chronic rejection, and ductopenia of 50% or more but not with other histologic lesions. In children, class I HED of the donor was also associated with acute rejection independent of the presence of DSAs. There was no effect of either donor class II HED or recipient class I or class II HED on the incidence of liver lesions in adults and children. Thus, HED calculated from the HLA alleles of the donor had a much stronger influence on liver transplant success than HLA compatibility. The higher the HED of a donor of liver graft, the more frequent rejection, and this was completely independent of the HLA compatibility of donors and recipients.

These findings allowed the investigators to conclude, “Class I HED of the donor predicts acute or chronic rejection of liver transplant. This novel and accessible prognostic marker could orientate donor selection and guide immunosuppression.”

The study was published in the August 24, 2021, online edition of the journal Annals of Internal Medicine.

Related Links:
Assistance Publique, Hôpitaux de Paris

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.